CJC-1295 (with DAC) vs CJC-1295 (no DAC) / Mod GRF 1-29
Compare CJC-1295 (with DAC), CJC-1295 (no DAC) / Mod GRF 1-29: half-life, time to Cmax, dosing interval, published dose ranges and titration — citation-backed, research use only.
| CJC-1295 (with DAC)CJC-1295, DAC:GRFView CJC-1295 (with DAC) → | CJC-1295 (no DAC) / Mod GRF 1-29Modified GRF 1-29, Sermorelin analogView CJC-1295 (no DAC) / Mod GRF 1-29 → | |
|---|---|---|
| Class | Growth Hormone Secretagogue | Growth Hormone Secretagogue |
| Route | Subcutaneous | Subcutaneous |
| Plasma half-life | ~7.0 days (168 h) | ~30 min |
| Time to Cmax | 12 h | ~15 min |
| Typical interval | Once weekly | Three times daily |
| Published dose range | 1–2 mg | 0.1–0.2 mg |
| Titration ladder | No preset ladder | No preset ladder |
| Summary | GHRH analog with Drug Affinity Complex — albumin binding extends half-life to ~1 week. | GHRH analog without albumin binding. Very short half-life — preserves the natural GH pulse pattern. |
Source references
CJC-1295 (with DAC)
- Teichman SL et al., J Clin Endocrinol Metab 91:799 (half-life 5.8–8.1 d) (2006)
CJC-1295 (no DAC) / Mod GRF 1-29
- Ionescu M & Frohman LA, J Clin Endocrinol Metab 91:4792 (2006)
For research use only. Not for human consumption. This tracker visualises only the doses you have logged or scheduled — it does not recommend dose sizes, does not suggest what to take, and is not pharmacokinetically calibrated. It is not medical advice and does not diagnose, treat, cure, or prevent any condition. Consult a licensed clinician before making any medical decision.